ReviewAnnals of cardiothoracic surgery2026
The value of preoperative risk scores prior to tricuspid valve interventions: The TRI-SCORE and beyond.
Review in Annals of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tricuspid regurgitation (TR) is increasingly recognized as a condition associated with poor clinical outcomes, including reduced quality of life, progressive right-sided heart failure, and increased mortality. Its heterogeneous etiologies and systemic consequences, affecting both cardiac and extracardiac organs such as the kidneys and liver, make patient management particularly challenging. Accurate risk stratification and timely intervention are therefore essential. The 2025 European Society of Cardiology and European Association for Cardio-Thoracic Surgery Guidelines acknowledge the multifaceted nature of TR and emphasize the need for evaluation in expert centers through multidisciplinary Heart Team discussions. In this context, the TRI-SCORE, initially developed to predict in-hospital mortality after isolated tricuspid valve (TV) surgery, has been incorporated into the guideline decision-making algorithm as a key risk assessment tool to support therapeutic selection. This simple eight-variable model demonstrated excellent prognostic predictive performance and has been validated across several international cohorts of patients conservatively treated or who underwent a surgical or transcatheter intervention. Compared with other surgical scores such as EuroSCORE II, Model for End-Stage Liver Disease (MELD)/MELD-XI, or the Society of Thoracic Surgeons isolated TV surgery model, the TRI-SCORE is disease-specific, simple, and offers superior predictive value. It helps identify patients most likely to benefit from intervention, providing a practical framework for integrating disease stage, procedural risk, and expected benefit. Both surgical and transcatheter therapies may improve prognosis when performed early, whereas delayed referral at advanced stages offsets their potential benefit. The systematic use of TRI-SCORE within the Heart Team can therefore refine patient selection, guide the timing of intervention, and support personalized, lifetime management of TR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.